The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 study.
Zelenetz AD, Jurczak W, Ribrag V, Linton K, Collins GP, Jiménez JL, Bishton M, Dholaria B, Mengarelli A, Phillips TJ, Sungala N, Musuraca G, Sheehy O, Van Den Neste E, Odera M, Miao L, Gold DP, Ghalie RG, Zinzani PL.
Zelenetz AD, et al. Among authors: gold dp.
Hemasphere. 2024 Aug 6;8(8):e138. doi: 10.1002/hem3.138. eCollection 2024 Aug.
Hemasphere. 2024.
PMID: 39108321
Free PMC article.